Business
Royal Oldham SSD service update
Royal Oldham SSD service update.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n\n\nCreo Medical Group plc\n(\"Creo\" the \"Company\" or the \"Group\")\n \nRoyal Oldham SSD service going from strength to strength\n40 cases completed in record time, with patients and waiting lists experiencing immediate benefits\n \nCreo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, provides an update on the implementation of its technology within The Royal Oldham Hospital (\"Royal Oldham\"). On 17 May, Creo announced that Royal Oldham had become the first NHS hospital to immediately implement CROMA and Speedboat™ Inject across multiple endoscopy rooms, putting in place weekly lists for multiple SSD (Speedboat Submucosal Dissection) cases.\n \nThe hospital has now treated over 40 patients using the new service, representing the fastest time for any NHS hospital to reach the landmark, with exceptional results for patients, the hospital and its staff. Multiple doctors at the hospital have already progressed through Creo's Pioneer Programme mentoring stage and are independently treating regular lists of patients presenting with complex, high-risk lesions in the colon.\n \nCreo has a target base for the Speedboat range of products of more than 350 NHS hospitals, with each SSD procedure demonstrated to save the NHS up to £10k when compared to traditional surgery, alongside a typically far shorter hospital stay and significantly lower risk of complications. There are 23 NHS England healthcare settings that have now adopted SSD.\n \nDr Sal Khalid, Consultant Gastroenterologist at the Royal Oldham Hospital, said: \"I'm very pleased with the outcomes the Speedboat Inject device is facilitating for our patients, allowing our advanced endoscopists to remove complex high-risk lesions and even early cancer without the patient requiring invasive surgical treatment.\n \n\"Almost all bowel cancers start as a lesion, and so having the technology now available to us to cut deeper and more safely through the layers of the bowel when removing a lesion enables us to ensure that it's completely removed and reduce the chances of patients requiring an operation.\n \n\"It's already clear that this will have a lasting effect, with the treatment reducing the chances of recurrence from 15% to 1% and potentially providing a cure for l...